Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

 Elanco Sells Victoria, PEI, Canada R&D Facility to The Center for Aquaculture Technologies Canada (CATC)

December 24, 2019 GMT

GREENFIELD, Ind.--(BUSINESS WIRE)--Dec 24, 2019--

Elanco Animal Health Incorporated (NYSE: ELAN) has signed an agreement to sell its Victoria, Prince Edward Island (PEI) aqua research and development facility to The Center for Aquaculture Technologies Canada, a leading aquaculture R&D and contract research services company with an established presence in PEI.

The site was added to the Elanco footprint as part of the Novartis acquisition in 2015, and a source of innovative products and solutions to some of the industry’s greatest needs. Elanco will shift this important capability into its other existing R&D facilities.

“We are extremely grateful for the efforts, hard work and all contributions everyone at the Victoria R&D facility has made to the Elanco pipeline and the industry,” said Aaron Schacht, executive vice president of Innovation, Regulatory and Business Development at Elanco. “We are equally pleased to reach an outcome that keeps the site operational in the Victoria community with a group that values furthering the future of aquaculture.”

John Buchanan, CEO of CATC, commented, “We are excited to continue to grow our aquaculture health and nutrition research services business in PEI, and have great plans for use of the facility.”

In September, Elanco announced its decision to seek a buyer for the Victoria R&D site. Aquaculture and the company’s Charlottetown manufacturing facility continue to be a key component of Elanco’s growth, as evidenced by the company’s workforce expansion and capital investments at the site over the past two years.

Today’s development is another step in Elanco’s journey to build an agile, stand-alone animal health company. These efforts build on the company’s productivity agenda, driving margin expansion through enhanced efficiency.

The transaction is expected to close at the beginning of the first quarter in 2020. Financial terms of the deal were not disclosed.

About Elanco

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for approximately 5,700 employees. At Elanco, we’re driven by our vision of food and companionship enriching life - all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191224005021/en/

CONTACT: Investor Contact: Jim Greffet (317) 383-9935 orGreffet_james_f@elanco.com

Media Contact: Colleen Parr Dekker (317) 276-4076 orcolleen_parr_dekker@elanco.com



SOURCE: Elanco Animal Health Incorporated

Copyright Business Wire 2019.

PUB: 12/24/2019 07:30 AM/DISC: 12/24/2019 07:30 AM